Related Experiment Videos

Old and newer biomarkers in heart failure: from pathophysiology to clinical significance

Nasser Sherwi1, Pierpaolo Pellicori, Anil C Joseph

  • 1Department of Academic Cardiology, Hull and East Yorkshire Medical Research and Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|July 13, 2013
PubMed

Insights

Diagnosing heart failure can be challenging. Measuring natriuretic peptides and exploring other biomarkers, potentially in combination, can improve diagnosis, risk stratification, and personalized treatment for heart failure patients.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • Clinical examination and cardiac function tests are often insufficient for accurate heart failure diagnosis.
  • Natriuretic peptides are established biomarkers for heart failure diagnosis and risk stratification.
  • Understanding diverse pathophysiological pathways is crucial for identifying at-risk patients and those with adverse outcomes.

Purpose of the Study:

  • To evaluate the role of natriuretic peptides and alternative biomarkers in diagnosing and managing heart failure.
  • To explore the potential of a multi-marker approach for improved diagnostic accuracy and patient stratification.
  • To identify patient phenotypes that may benefit from individualized heart failure therapy.

Main Methods:

  • Review of current literature on natriuretic peptides and novel biomarkers in heart failure.
  • Analysis of the diagnostic and prognostic utility of various biomarkers.
  • Discussion on the potential clinical integration of a multi-marker strategy.

Main Results:

  • Natriuretic peptides aid in heart failure diagnosis and risk assessment.
  • Alternative biomarkers offer insights into disease mechanisms and prognosis.
  • A multi-marker approach shows promise for enhanced diagnostic accuracy and phenotyping.

Conclusions:

  • While natriuretic peptides are valuable, a broader biomarker panel may be necessary for comprehensive heart failure management.
  • Future research should focus on validating novel biomarkers and developing multi-marker strategies.
  • Personalized therapy based on identified heart failure phenotypes is a key future direction.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...